Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
carries a substantial risk of severe and prolonged illness; treatment options are currently …

Background Multiple early reports of patients admitted to hospital with COVID-19 showed
that patients with chronic respiratory disease were significantly under-represented in these …

Background A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …

Objectives To the best of our knowledge, there is no published study regarding use of IFN β-
1a in the treatment of severe COVID-19. In this randomized clinical trial efficacy and safety of …

Background To date, only monoclonal antibodies have been shown to be effective for
outpatients with COVID-19. Interferon lambda-1 is a type III interferon involved in innate …

Coronavirus disease 2019 (COVID-19), caused by the highly contagious novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a worldwide pandemic …

To the best of our knowledge, there is no published study on the use of interferon β-1a (IFN
β-1a) in the treatment of severe COVID-19. In this randomized clinical trial, the efficacy and …

Severe acute respiratory syndrome coronavirus 2 principally weakens the hosts' innate
immune system by impairing the interferon function and production. Type I interferons (IFNs) …

The global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing,
with no approved antiviral intervention. We describe here the effects of treatment with …

In this study, efficacy and safety of interferon (IFN) β-1b in the treatment of patients with
severe COVID-19 were evaluated. Among an open-label, randomized clinical trial, adult …